A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones

Mary Ellen Taplin, Judith Manola, William K. Oh, Philip W. Kantoff, Glenn J. Bubley, Matthew Smith, Diana Barb, Christos Mantzoros, Edward P. Gelmann, Steven P. Balk

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones'. Together they form a unique fingerprint.

Medicine & Life Sciences